Cytochroma appoints co-founder Dr. P. Martin Petkovich as full-time Chief Scientific Officer

    MARKHAM, ON, March 12 /CNW/ - Cytochroma Inc. announced today the
appointment of Dr. P. Martin Petkovich as full-time Chief Scientific Officer.
    In his newly expanded role, Dr. Petkovich will help propel the
development and commercialization of promising new Vitamin D products thereby
providing nephrologists with more effective tools to treat disorders and
deficiencies related to vitamin D hormone deficiency in chronic kidney disease
    "I am excited by Cytochroma's exceptional product pipeline and its proven
ability to advance new products into the clinic," said Dr. Petkovich. "I
believe that this combination will ensure Cytochroma's success in bringing
excellent new therapies to CKD patients."
    Dr. Petkovich received his PhD from the University of Toronto in 1986 and
completed a post-doctoral fellowship in the laboratory of Dr. Pierre Chambon
in Strasbourg, France. Thereafter, he joined Queen's University where he
continues to hold a Full Professorship. Dr. Petkovich is known internationally
as an expert in vitamin and hormone regulation of gene expression and
metabolism. Dr. Petkovich co-founded Cytochroma in 1996 at Queen's University
and has led the discovery of a number of innovative products with applications
in dermatology and in CKD. To date, Dr. Petkovich has served as a part-time
consultant to Cytochroma.
    "Dr. Petkovich brings to Cytochroma a wealth of scientific knowledge and
research experience which greatly strengthens the company's ability to develop
and commercialize proprietary technologies directed toward CKD," stated
Charles W. Bishop, PhD, Cytochroma's President and CEO. "We welcome Dr.
Petkovich as he begins a greater involvement with Cytochroma."

    About Chronic Kidney Disease and Secondary Hyperparathyroidism

    Vitamin D and its analogs are currently used to treat secondary
hyperparathyroidism in patients with CKD or end-stage renal disease. According
to the National Kidney Foundation, more than nine million North American
patients suffer from moderate to severe CKD. Many develop vitamin D deficiency
and secondary hyperparathyroidism which, if untreated, can cause debilitating
bone diseases and increased patient morbidity and mortality.

    About Cytochroma Inc.

    Cytochroma ( is an integrated specialty pharmaceutical
company engaged in the development and commercialization of proprietary
products to treat and prevent the clinical consequences of diseases and
disorders related to vitamin D hormone deficiency. The Company has an advanced
portfolio of new products targeting vitamin D deficiency and secondary
hyperparathyroidism in patients with moderate to severe chronic kidney disease
and end-stage renal disease. In addition, the Company is developing novel
vitamin D therapies to treat hyperproliferative disorders such as cancer and

For further information:

For further information: Eric J. Messner, Vice President, Commercial
Operations, (905) 479-5306 ext. 338,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890